TB Alliance announces new drug discovery program with GlaxoSmithKline
... ... ...Teleconference to provide overview on launch of broad discovery portfolio to improve the treatment of tuberculosis (TB). The program significantly enhances the TB drug pipeline by adding several novel classes of compounds that use new mechanisms of action. Briefings from the TB Alliance on status of TB drug pipeline and discussion with GlaxoSmithKline, patient and public health group...GlaxoSmithKline receives unanimous favorable recommendation by FDA Advisory Committee for Boostrix
PHILADELPHIA, PA, March 15, 2005 GlaxoSmithKline (NYSE: GSK) today announced that its booster vaccine candidate, BoostrixTM [Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed (Tdap)] received a unanimous favorable recommendation from the Vaccines and Related Biological Products Advisory Committee of the U.S. Food and Drug Administration (FDA). Currently, there...Emory, GlaxoSmithKline, NIMH enter public-private partnership to develop new drugs for depression
ATLANTA, US; LONDON, UK -- Through a unique partnership among academia, industry, and government, a team of scientists from Emory University School of Medicine, GlaxoSmithKine (GSK), and the National Institute of Mental...Health (NIMH) will work together to accelerate the development of drugs to treat depression and other mood disorders. The new venture, funded through a $4.9 million, five-year g...GlaxoSmithKline Drug Discovery and Development Research Grant Program 2003
Research Triangle Park, N.C. (November 20, 2003) Five researchers have been awarded 2003 GlaxoSmithKline (GSK) Drug Discovery and Development Research Grants for their efforts to develop new pharmaceutical strategies to combat HIV, the virus that causes AIDS. The recipients, who will share $500,000 in grant money, are: Paul Bieniasz, Ph.D., Associate Professor, Aaron Diamond AIDS Research Cente...GlaxoSmithKline Drug Discovery and Development Research Grant Program 2003
Research Triangle Park, NC (April 10, 2003) - GlaxoSmithKline (GSK) will award $500,000 in grants for innovative HIV/AIDS drug research in recognition of the need to produce new alternatives and hope in the fight against the HIV/AIDS pandemic. ...Applications are now being solicited for 2003 research grants and must be submitted by July 31. The one-time research grants range from $25,000 to $150...Six HIV and AIDS researchers will split $500,000 as this year's recipients of the GlaxoSmithKline (GSK) Drug Discovery and Development Award. The unrestricted research award program is funded by GSK to support independent, innovative and novel research in the development of HIV/AIDS therapeutics. ...An Expert Review Board, composed of researchers who are leaders in the field of HIV/AIDS, indepe...In recognition of the need for pioneers to produce new alternatives and hope against the HIV/AIDS...pandemic,GlaxoSmithKline (GSK) is offering $500,000 in unrestricted awards for innovative HIV/AIDS drug research....... Applications are now being solicited for 2002 awards and must be submitted by July 31. The one-time awards are from $25,000 to $150,000 and are intended to further the developme...